Chronic chlamydia pneumoniae infection in patients with coronary disease. Relation with increased fibrinogen values;Infeccíon crónic por Chlamydia pneumoniae en pacientes con enfermedad coronaria. Relación con el incremento de los valores de fibrinógeno

Medicina Clinica

Volumn 119, Issue 15, 2002, Pages 561-564

  Fernández Miranda, Consuelo ^a   Paz, Manuel ^a   Aranda, José Luis ^a   Fuertes, Antonio ^a   de la Cámara, Agustin Gómez ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

C reactive protein; Chlamydia pneumoniae; Coronary disease; Fibrinogen

Indexed keywords

BACTERIUM ANTIBODY; BIOLOGICAL MARKER; C REACTIVE PROTEIN; FIBRINOGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ADULT; AGE; AGED; ANTIBODY TITER; ARTICLE; BLOOD CLOTTING DISORDER; CARDIOVASCULAR RISK; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE MARKER; ENZYME IMMUNOASSAY; FEMALE; FIBRINOGEN BLOOD LEVEL; GENDER; HUMAN; HYPERCHOLESTEROLEMIA; HYPERFIBRINOGENEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREVALENCE; SMOKING; SPAIN; CHRONIC DISEASE; CORONARY ARTERY ATHEROSCLEROSIS; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; MICROBIOLOGY; MIDDLE AGED;

ANTIBODIES, BACTERIAL; C-REACTIVE PROTEIN; CHLAMYDIA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; CHRONIC DISEASE; CORONARY ARTERIOSCLEROSIS; FEMALE; FIBRINOGEN; HUMANS; IMMUNOGLOBULIN M; MALE; MIDDLE AGED;

EID: 0037010273     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-7753(02)73499-4     Document Type: Article

References (40)

1. Saikku P, Leinonen M, Mattila K, Ekman MR, Nieminen MS, Makela PH, et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988;2:983-6.
2. Saikku P, Leinomen M, Tenkanen L, Linnanmäki E. Ekman MR, Manninen V, et al. Chronic Chlamydia pneumonia infection as a risk factor for coronary heart disease in the Helsinki heart study. Ann Intern Med 1992;116:273-8.
3. Blasi F, Consentini R, Roccanelli R, Massari FM, Arosio C, Tarsia P, et al. Possible association myocardial infarction in patients younger than 65 years of age. Chest 1997;112:309-12.
4. Strachan DP, Carrington D, Mendall MA, Ballam L, Morris J, Butland BK, et al. Relation of Chlamydia pneumoniae serology to mortality and incidence of ischaemic heart disease over 13 years in the Caerphilly prospective heart disease study. BMJ 1999;318:1035-40.
5. Davidson M, Kuo CC, Middaugh JP, Campbell LA, Wang SP, Newman WP III. Confirmed previous infection with Chlamydia pneumoniae (TWAR) and its presence in early coronary atherosclerosis. Circulation 1998;98:628-33.
6. Melnick SL, Shahar E, Folsom AR, Grayston JT, Sorlie PD, Wang S-P, et al. Past infection by Chlamydia pneumoniae strain TWAR and asymptomatic carotid athersoclerosis. Am J Med 1993; 95; 499-504.
7. Cook PJ, Honeybourne D, Lip GYH, Beevers DG, Wise R, Davies P. Chlamydia pneumoniae anti-body titers are significantly associated with acute stroke and transient cerebral ischemia. Stroke 1998;29:404-10.
8. Sander D, Winbeck K, Klingelhöfer J, Elgen T, Conrad B. Enhanced progression of early carotid atherosclerosis is related to Chlamydia pneumoniae (Taiwan Acute Respiratory) seropositivity. Circulation 2001;103:1390-5.
9. Kuo CC, Grayston JT, Campbell LA, Goo YA, Wissler RW, Benditt EP. Chlamydia pneumoniae (TWAR) in coronary arteris of young adults (15-34 years old). Proc Natl Acad Sci USA 1995;92: 6911-4.
10. Muhlestein JB, Hammond EH, Carlquist JF, Radicke E, Thomson MJ, Karagounis LA, et al. Increased incidence of Chlamydia species within the coronary arteris of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease J Am Coll Cardiol 1996;27: 1555-61.
11. Gaydos CA, Summersgill JT, Sahney NN, Ramirez JA, Quinn TC. Replication of Chlamydia pneumonia in vitro human macrophages, endothelial cells, and aortic artery smooth muscle cells. Infect Immun 1996;64:1614-20.
12. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340:115-26.
13. Patel P, Mendall MA, Carrington D, Strachan DP, Leatham E, Molineaux N, et al. Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. BMJ 1995;311:711-4.
14. Tütüncü NB, Güvener N, Tütüncü T, Yilmax M., Güvener M, Böke E, et al. Chlamydia pneumoniae seropositivity correlates with serum fibrinogen and lipoprotein a levels: any role in atherosclerosis? Endocr J 2001;48:269-74.
15. Choussat R, Montalescot G, Collet JP, Jardel C, Ankri A, Fillet AM, et al. Effect of prior exposure to Chlamydia pneumoniae, Helicobacter pylori or Cytomegalovirus on the degree of inflammation and one-year prognosis of patients with unstable angina pectoris or non-Q-wave acute myocardial infarction. Am J Cardiol 2000;86:379-84.
16. Chandra HR, Chodhary N, O'Neill C, Boura J, Timmis GC, O'Neill WW. Chlamydia pneumoniae exposure and inflammatory markers in acute coronary syndrome (CIMACS). Am J Cardiol 2001; 88:214-8.
17. Sionis A, Bosch X, Hage M, Miranda F, Vidal J, Díez-Aja S, et al. Valor pronóstico de la seropositividad IgG para Chlamydia pneumoniae en pacientes con angina inestable [resumen]. Rev Esp Cardiol 1999;52(Supl 4):76.
18. Lapetra J, Sanots JM, Gil-Peralta A, Mayoral E, González-Marcos JR. Chlamydia pneumoniae y arteriosclerosis. Rev Neurol 1999;28:251-5.
19. Linares-Palomino J, Gutiérrez J, López-Espada C, Ros E, Moreno J, Pŕez T, et al. Chlamydia pneumoniae y enfermedad cerebrovascular. Rev Neurol 2001;32:201-6.
20. Mendall MA, Carrington D, Strachan D, Patel P, Molineaux N, Levi J, et al. Chlamydia pneumoniae: risk factors for seropositivity and association with coronary heart disease. J Infect 1995; 30: 121-8.
21. Gutiérrez J, Mendoza J, Fernández F, Linares-Palomino J, Soto MJ, Maroto MC. ELISA test to detect Chlamydophila pneumoniae IgG. J Basic Microbiol 2002;42:13-8.
22. Montalescot G, Collet JP, Choussat R, Thomas D. Fibrinogen as a risk factor for coronary heart disease. Eur Heart J 1998;19(Suppl H):11-7.
23. García-Moll X, Guindo J, Kaski JC. Proteína C reactiva como factor de riesgo coronario. Med Clin (Barc) 2001;117:303-8.
24. Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001;103:1933-8.
25. Strandberg TE, Vanhanen H, Tikkanen MJ. Effect of statins on C-reactive protein in patients with coronary artery disease. Lancet 1999;353: 118-9.
26. Song JC, White CM. Do HMG-CoA reductase inhibitors affect fibrinogen? Ann Pharmacother 2001;35:236-41.
27. Rosenson RS, Tangney CC, Schaefer EJ. Comparative study of HMG-CoA reductase inhibitors on fibrinogen. Atheroslerosis 2001;155:463-6.
28. Hahn DL, Golubjatnikov R. Smoking is a potential confounder of the Chlamydia pneumoniae-coronary artery disease association. Arterioscler Thromb 1992;12:945-7.
29. Karvonen M, Tuomilehto J, Pitkaniemi J, Naukkarine A, Saikku P. Importance of smoking for Chlamydia pneumoniae seropositivity. Int J Epidemiol 1994;23:1315-21.
30. Wiesli P, Maly FE, Meniconi A, Czerweka W, Hoffmann U, Vetter W. Chlamydia pneumoniae seropositivity and hyperthomocysteinemia are linked in patients with atherosclerosis. Clin Chem 2001;47:1304-6.
31. Mensa J, Sänchez F, Martínez JA, Vidal J. Chlamydia pneumoniae y aterosclerosis. Med Clin (Barc) 2001;2:61-6.
32. Summersgill JT, Molestina RE, Miller RD, Ramirez JA. Interactions of Chlamydia pneumoniae with human endothelial cells. J Infect Dis 2000; 181(Suppl 3):479-82.
33. Miettinen H, Lehto S, Saikku P, Haffner SM, Ronnemaa T, Pyorala, et al. Association of Chlamydia pneumoniae and acute coronary heart disease events in noninsulin dependent diabetic and non-diabetic subjects in Finland. Eur Heart J 1996;17:682-8.
34. Ridker PM, Kundsin RB, Stampfer MJ, Poulin S, Hennekens CH. Prospective study of Chlamydia pneumoniae IgG seropositivity and risks of future myocardial infarction. Circulation 1999;99:161-4.
35. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, et al. Chlamydia pneumoniae IgG titres and coronary heart disease: prospective study and meta-analysis. BMJ 2000; 321:208-13.
36. Wald NJ, Law MR, Morris JK, Zhou X, Wong Y, Ward ME. Chlamydia pneumoniae infection and mortality from ischaemic heart disease: large prospective study. BMJ 2000;321:204-7.
37. Gurfinkel E, Bozowich G, Daroca A, Beck E, Mautner B. Randomised trial of roxithromycin in non-Q-wawe coronary syndromes: ROXIS pilot study. ROXIS study group. Lancet 1997;350:404-7.
38. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm A. Elevated Chlamydia pneumoniae antibodies, cardiovascular events and azithromycin in male survivors of myocardial infarction. Circulation 1997;96:404-7.
39. Parchure N, Zouridakis EG, Kaski JC. Effect of azithromycin treatment on endotelial function in patients with coronary artery disease and evidence of Chlamydia pneumoniae infection. Circulation 2002;105:1298-303.
40. Anderson JL, Muhlestein JB, Carlquist J, Allen A, Trehan S, Nielson C, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence of Chlamydia pneumonia infection: the azithromycin in coronary artery disease: elimination of myocardial infection with Chlamydia (ACA-DEMIC) study. Circulation 1999; 99:1540-7.